Capricor Therapeutics, Inc. (NASDAQ:CAPR) is reporting third quarter earnings results on Thursday 12th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.37 per share.
For the full year, analysts predict revenues of $ 0.24 million, while looking forward to loss of $ 1.46 per share.
Previous Quarter Performance
Capricor Therapeutics, Inc. communicated loss for the second quarter of $ 0.23 per share, from the revenue of $ 0.05 million. The quarterly revenues reduced 87.80 percent compared with the same quarter last year. Street analysts expected Capricor Therapeutics, Inc. to report loss of $ 0.37 per share on revenue of $ 0.21 million for the second quarter. The bottom line results beat street analysts by $ 0.14 or 37.84 percent, at the same time, top line results fell short of analysts by $ 0.16 million or 76.19 percent.
Stock Performance
Shares of Capricor Therapeutics, Inc. traded up $ 0.46 or 10.87 percent on Wednesday, reaching $ 4.69 with volume of 1.31 million shares. Capricor Therapeutics, Inc. has traded high as $ 4.78 and has cracked $ 4.18 on the downward trend
The closing price of $ 4.69, representing a 380.68 % increase from the 52 week low of $ 0.88 and a 65.67 % decrease over the 52 week high of $ 12.32.
The company has a market capital of $ 94.98 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Capricor Therapeutics, Inc. will be hosting a conference call at 4:30 PM eastern time on 12th November 2020, to discuss its 3Q20 financial results with the investment community. The participants may dial, 877-451-6152 (United States) or 201-389-0879 (International), when prompted, enter passcode 13712434 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.capricor.com
Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, or DMD, and other medical conditions. The companys development stage drug candidates for cardiosphere-derived cells include CAP-1002 that completed phase I/II clinical trial in subjects with DMD; phase I clinical trial for treating heart failure; and phase I/II clinical trial in subjects with myocardial infarction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of inflammatory conditions.
